drug pricing · cms finalizes
An emergent story thread — signals the timeline clustered together from their own shared language, not a fixed topic.
5 signals in the last 30 days Structural & Policy Drivers
-
CMS Finalizes New Mandatory Drug Payment Model to Deliver Lower Drug Prices for Beneficiaries in Original Medicare Part B
CMS Finalizes New Mandatory Drug Payment Model to Deliver Lower Drug Prices for Beneficiaries in Original Medicare Part B
-
CMS finalizes model that aims to bring most-favored nation pricing to Part B
The Trump administration has finalized a new model that aims to bring its most-favored nation pricing approach to Medicare Part B.
-
CMS finalizes new drug pricing model: 7 notes
CMS has finalized the Global Benchmark for Efficient Drug Pricing (GLOBE) Model, a mandatory payment model that will tie Medicare Part B drug rebates to prices paid in 19 reference countries, according to a Sept. 30 CMS news release. Here are seven things to know: The post CMS finalizes new drug pricing model: 7 notes appeared first on Becker's Payer Issues | Payer News .
-
PhRMA launches new legal challenge as CMS brings 'most favored nation' pricing to Medicare Part B
As the Trump administration advances plans to bring its “most favored nation” drug pricing model to Medicare Part B, the pharmaceutical industry’s top lobbying group is pushing back in court.
-
Global Benchmark for Efficient Drug Pricing (GLOBE) Model
This final rule implements the Global Benchmark for Efficient Drug Pricing Model (GLOBE Model), a new mandatory Medicare payment model under section 1115A of the Social Security Act. The GLOBE Model will test whether a payment model that uses an alternative method for calculating Medicare Part B drug inflation rebate amounts for certain separately payable Medicare Part B drugs and biological products reduces costs for Original Medicare (OM) beneficiaries and the Medicare program while preserv...